Morning Versus Evening Administration of Intranasal Mometasone Furoate in Seasonal Allergic Rhinitis: A Baseline-Adjusted Comparative Study
Open Access
- 24 April 2026
- journal article
- Published by SAGE Publications in Ear, Nose & Throat Journal
Abstract
Objective: To compare the effects of morning versus evening once-daily administration of intranasal mometasone furoate on nasal symptoms, sleep quality, daytime sleepiness, and quality of life in patients with moderate-to-severe seasonal allergic rhinitis (SAR). Methods: This prospective, randomized, single-blind study included 120 adults with SAR who received intranasal mometasone furoate (200 μg once daily) either in the morning or in the evening for 15 days. Outcomes were assessed using the Total Nasal Symptom Score, Rhinitis Quality of Life Scale, Pittsburgh Sleep Quality Index, and Epworth Sleepiness Scale. Baseline-adjusted comparisons between treatment groups were performed using analysis of covariance. Results: Both treatment groups showed significant posttreatment improvements in nasal symptoms, sleep quality, daytime sleepiness, and rhinitis-related quality of life. After adjustment for baseline values, no statistically significant differences were observed between morning and evening dosing for any outcome measure (all P > .05). Baseline disease severity emerged as the primary determinant of posttreatment outcomes, accounting for a substantial proportion of outcome variability, whereas dosing time showed no clinically meaningful effect. Conclusion: Once-daily intranasal mometasone furoate provides comparable clinical benefits regardless of whether it is administered in the morning or in the evening in patients with moderate-to-severe SAR. These findings suggest that dosing time has limited clinical relevance for long-acting intranasal corticosteroids, allowing treatment to be guided by patient preference without compromising efficacy.Keywords
This publication has 24 references indexed in Scilit:
- Effects of combination treatment with tezepelumab and allergen immunotherapy on nasal responses to allergen: A randomized controlled trialJournal of Allergy and Clinical Immunology, 2022
- Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines—2016 revisionJournal of Allergy and Clinical Immunology, 2017
- The efficacy of fluticasone furoate administered in the morning or evening is comparable in patients with persistent asthmaRespiratory Medicine, 2016
- The efficacy of once-daily fluticasone furoate/vilanterol in asthma is comparable with morning or evening dosingRespiratory Medicine, 2013
- Intranasal mometasone furoate therapy for allergic rhinitis symptoms and rhinitis-disturbed sleepAnnals of Allergy, Asthma & Immunology, 2010
- Comparable morning versus evening administration of once-daily mometasone furoate dry powder inhalerRespiratory Medicine, 2008
- Reliability and validity studies of the Turkish version of the Epworth Sleepiness ScaleSleep and Breathing, 2007
- Chronobiology and chronotherapy of allergic rhinitis and bronchial asthmaAdvanced Drug Delivery Reviews, 2007
- Pharmacologic approaches to daytime and nighttime symptoms of allergic rhinitisJournal of Allergy and Clinical Immunology, 2004
- Circadian and circannual rhythms of allergic rhinitis: An epidemiologic study involving chronobiologic methodsJournal of Allergy and Clinical Immunology, 1988